SG11201807809XA - A transient commensal microorganism for improving gut health - Google Patents

A transient commensal microorganism for improving gut health

Info

Publication number
SG11201807809XA
SG11201807809XA SG11201807809XA SG11201807809XA SG11201807809XA SG 11201807809X A SG11201807809X A SG 11201807809XA SG 11201807809X A SG11201807809X A SG 11201807809XA SG 11201807809X A SG11201807809X A SG 11201807809XA SG 11201807809X A SG11201807809X A SG 11201807809XA
Authority
SG
Singapore
Prior art keywords
international
davis
pct
transient
english
Prior art date
Application number
SG11201807809XA
Inventor
David Kyle
Samara Freeman-Sharkey
Steven Frese
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of SG11201807809XA publication Critical patent/SG11201807809XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101111101101110111001101111101111011111 International Bureau .. .... ..Yejd ..... .....1 (10) International Publication Number (43) International Publication Date WO 2017/156550 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) (21) (22) (25) (26) (30) (71) (72) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 35/745 (2015.01) A61K 31/702 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/00 (2006.01) A61K 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/70 (2006.01) A61K 35/74 (2015.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/022209 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 13 March 2017 (13.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Publication Language: English ZA, ZM, ZW. Priority Data: (84) Designated States (unless otherwise indicated, for every 62/307,420 11 March 2016 (11.03.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Applicant: EVOLVE BIOSYSTEMS INC. [US/US]; TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 2121 2nd Street, Suite B107, Davis, CA 95618 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Inventors: KYLE, David; P.O. Box 119, Gualala, CA 95445 (US). FREEMAN-SHARKEY, Samara; 5248 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CL CM, GA, GN, GQ, Hamel Street, Davis, CA 95618 (US). FRESE, Steven; 9163 Olmos Lane, Davis, CA 95616 (US). GW, KM, ML, MR, NE, SN, TD, TG). Published: Agents: PEARLMAN, Anne, W. et al.; Hunton and Willi- ams LLP, 2200 Pennsylvania Avenue, NW, Washington, — with international search report (Art. 21(3)) D.C. 20037 (US). (74) Title: A TRANSIENT COMMENSAL MICROORGANISM FOR IMPROVING GUT HEALTH (54) 1 1-1 © ir) ir) ir) 1-1 IN 1-1 (57) 0 mals \" gosaccharides. 0 2 3 4 5 6 7 8 9 10 11 18 FIG. 1 : The inventions described herein relate generally to administering compounds to promote mucosal healing in mam - in need thereof including, but not limited to humans. The compounds may include bifidobacteria and mammalian milk oli -
SG11201807809XA 2016-03-11 2017-03-13 A transient commensal microorganism for improving gut health SG11201807809XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307420P 2016-03-11 2016-03-11
PCT/US2017/022209 WO2017156550A1 (en) 2016-03-11 2017-03-13 A transient commensal microorganism for improving gut health

Publications (1)

Publication Number Publication Date
SG11201807809XA true SG11201807809XA (en) 2018-10-30

Family

ID=59789754

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807809XA SG11201807809XA (en) 2016-03-11 2017-03-13 A transient commensal microorganism for improving gut health

Country Status (8)

Country Link
US (1) US20200046782A1 (en)
EP (1) EP3426270A4 (en)
CN (1) CN109414464A (en)
AU (1) AU2017230187A1 (en)
BR (1) BR112018068261A2 (en)
CA (1) CA3017357A1 (en)
SG (1) SG11201807809XA (en)
WO (1) WO2017156550A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822497C (en) 2010-12-31 2020-07-28 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
SG191392A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MY182335A (en) 2011-07-22 2021-01-19 Abbott Lab Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MY169326A (en) 2011-08-29 2019-03-21 Abbott Lab Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2018215961A1 (en) * 2017-05-24 2018-11-29 Glycom A/S Synthetic composition comprising oligosaccharides and its use in medical treatment.
WO2019112054A1 (en) * 2017-12-08 2019-06-13 森永乳業株式会社 Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria
CN109481476B (en) * 2018-12-29 2021-09-07 重庆第二师范学院 Application of lactobacillus fermentum CQPC04 in preparing food or medicine for improving ulcerative colitis
AU2020257267A1 (en) * 2019-04-17 2021-11-18 Nutech Ventures Compositions including novel microbes with enhanced persistence, synergistic combinations of novel microbes and prebiotics, and methods for the isolation of such microbes
BR112022005578A2 (en) * 2019-09-24 2022-09-20 Prolacta Bioscience Inc COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY AND IMMUNE DISEASES
WO2021062049A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Beneficial bacteria and secretory immunoglobulin a
JP2021112165A (en) * 2020-01-20 2021-08-05 森永乳業株式会社 Composition, and food/beverage composition, nutritional composition and prepared milk
US20230255990A1 (en) * 2020-07-08 2023-08-17 Glycosyn LLC Use of 2'-fl for treatment of symptoms associated with autism spectrum disorder
MX2023001743A (en) * 2020-08-14 2023-04-21 Prolacta Bioscience Inc Human milk oligosaccharide compositions for use with bacteriotherapies.
AU2021332150A1 (en) * 2020-08-24 2023-03-23 Intrinsic Medicine, Inc. Immunomodulatory oligosaccharides for the treatment of autism spectrum disorder
CN114431484A (en) * 2020-11-06 2022-05-06 内蒙古伊利实业集团股份有限公司 Application of human milk oligosaccharide in improving resistance of intestinal tract to salmonella infection
AU2022207078A1 (en) * 2021-01-12 2023-06-29 Prolacta Bioscience, Inc. Synbiotic treatment regimens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2462252C2 (en) * 2006-03-10 2012-09-27 Н.В. Нютрисиа Application of indigestible saccharides for better adaptation of newborns
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
ES2680920T3 (en) * 2010-07-12 2018-09-11 The Regents Of The University Of California Bovine milk oligosaccharides
WO2012092155A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
WO2012158517A1 (en) * 2011-05-13 2012-11-22 Glycosyn LLC The use of purified 2'-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics
NL2007268C2 (en) * 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
EP3074020B1 (en) * 2013-11-15 2022-03-30 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
CN107249611A (en) * 2014-10-24 2017-10-13 进化生物系统股份有限公司 The Bifidobacterium of activation and its application process

Also Published As

Publication number Publication date
AU2017230187A1 (en) 2018-10-04
US20200046782A1 (en) 2020-02-13
CA3017357A1 (en) 2017-09-14
BR112018068261A2 (en) 2019-01-15
EP3426270A4 (en) 2020-04-01
WO2017156550A1 (en) 2017-09-14
EP3426270A1 (en) 2019-01-16
CN109414464A (en) 2019-03-01

Similar Documents

Publication Publication Date Title
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201811432WA (en) Rna for cancer therapy
SG11201811227QA (en) Method for facilitating maturation of the mammalian immune system
SG11201807912SA (en) Vaccine against rsv
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201808539WA (en) Mouth piece for cooling of oral tissue of a patient during chemotherapy treatment
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof